Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
September 14, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has...
Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:01 ET
|
Progenity, Inc.
Announced successful completion of the validation study PRO-104 for the Preecludia™ rule out test for preeclampsia and achievement of the primary endpoint of the study protocol Recently achieved...
Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
July 29, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™...
Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
June 02, 2021 07:00 ET
|
Progenity, Inc.
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
May 25, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd
May 21, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...